Difinsa53™ was designed and researched by the founders of ProTechSure Scientific, Inc, an outstanding multidisciplinary team of doctors and scientists at the University of Colorado Anschutz Medical Center in Aurora, Colorado.
Our team is guided by rigorous medical evidence and adhere to the highest ethical and U.S. Food and Drug Administration (FDA) standards. We continue to focus our research and development on innovative formulations of natural small-molecule compounds that absorb easily into the skin.
Meet Our Founders
L. Michael Glodé, MD
Dr. Glodé, a professor of medical oncology at the University of Colorado Anschutz Medical Center was instrumental in founding ProTechSure Scientific, Inc. through grants from the National Institutes of Health (NIH). He currently serves on the Company’s Board of Directors. Dr. Glodé has published more than 100 peer-reviewed articles in basic and applied cancer research, including key articles on the biologic properties of some of the ingredients of DIFINSA53™ Barrier Repair with Silybin. He is a Fellow of the American College of Physicians and the American Society of Clinical Oncology. He has been recognized by Best Doctors and other organizations as an academic leader in oncology research and patient care.
Theresa Pacheco, MD
Dr. Pacheco is a dermatologist and skin researcher at the University of Colorado Anschutz Medical Center. She practices medical and cosmetic dermatology and serves as an associate professor of dermatology. Dr. Pacheco has participated in the clinical development of many products and devices in skin medicine. Her professional interest is to bridge the gap between basic science research and patient-oriented research. This means early understanding of the clinical relevance of basic skin science research, followed by the appropriate design of clinical trials to further development of new therapies to treat skin disease.
Tom Anchordoquy, Ph.D.
Dr. Anchordoquy is a professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. He teaches the pharmaceutics and compounding courses in the professional pharmacy curriculum. His research focuses on drug delivery and drug formulation. This is a passion he has nurtured since his graduate school training 30 years ago. Dr. Anchordoquy is best known for his work on lipid-based carriers of drugs into the human body. He has also been involved in many early-phase R&D projects involving formulation of small molecules for oral, transdermal and parenteral delivery of drug therapies.
Rajesh Agarwal, Ph.D.
Dr. Agarwal is a noted cancer pharmacologist with a distinguished research career focused on discovering how to target tumor microenvironments by means of naturally-occurring small-molecule compounds, for use in new cancer prevention and treatment therapies. He a professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Agarwal has over 350 peer-reviewed publications and several book chapters to his name. He has given over 300 presentations in national and international scientific meetings worldwide. He is an elected Fellow in Pharmaceutical Sciences of the American Association for the Advancement of Science, and among many other distinctions, has received the Outstanding Achievement Award from the Society of American Asian Scientists in Cancer Research.